Do analysts prefer LTRN or ERNA?

Ernexa Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 646.27%. Given Ernexa Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Ernexa Therapeutics is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is LTRN or ERNA more profitable?

Ernexa Therapeutics' return on equity of -305.93% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -368.02% -148.62% Ernexa Therapeutics N/A -305.93% -169.86%

Is EVAX or ERNA more profitable?

Evaxion A/S's return on equity of -61.43% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -61.43% -34.23% Ernexa Therapeutics N/A -305.93% -169.86%

Do analysts rate ERNA or BYSI?

Ernexa Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 646.27%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ERNA or BYSI more profitable?

BeyondSpring's return on equity of 0.00% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics N/A -305.93% -169.86% BeyondSpring N/A N/A -28.88%

Is ERNA or NXTC more profitable?

NextCure's return on equity of -154.62% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics N/A -305.93% -169.86% NextCure N/A -154.62% -100.19%

Is ATOS or ERNA more profitable?

Atossa Genetics' return on equity of -102.99% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Atossa Genetics N/A -102.99% -85.78% Ernexa Therapeutics N/A -305.93% -169.86%

Ernexa Therapeutics (ERNA) Competitors

$4.02 -0.17 (-4.06%)

Closing price 04:00 PM Eastern

Extended Trading

$4.08 +0.07 (+1.62%)

As of 07:49 PM Eastern

Compare

ERNA vs. LTRN, EVAX, BYSI, NXTC, and ATOS

Should you buy Ernexa Therapeutics stock or one of its competitors? Ernexa Therapeutics's main competitors and comparable companies include Lantern Pharma (LTRN), Evaxion A/S (EVAX), BeyondSpring (BYSI), NextCure (NXTC), and Atossa Genetics (ATOS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ernexa Therapeutics compare to Lantern Pharma?

Lantern Pharma (NASDAQ:LTRN) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Ernexa Therapeutics' return on equity of -305.93% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-368.02%	-148.62%
Ernexa Therapeutics	N/A	-305.93%	-169.86%

In the previous week, Lantern Pharma's average media sentiment score of 0.00 equaled Ernexa Therapeutics'average media sentiment score.

Company	Overall Sentiment
Lantern Pharma	Neutral
Ernexa Therapeutics	Neutral

Ernexa Therapeutics has higher revenue and earnings than Lantern Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A
Ernexa Therapeutics	$580K	11.30	-$14.08M	-$14.35	N/A

Ernexa Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 646.27%. Given Ernexa Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Ernexa Therapeutics is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lantern Pharma has a beta of 2.3, meaning that its stock price is 130% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.61, meaning that its stock price is 161% more volatile than the broader market.

Summary

Ernexa Therapeutics beats Lantern Pharma on 9 of the 12 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Evaxion A/S?

Evaxion A/S (NASDAQ:EVAX) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Evaxion A/S presently has a consensus target price of $11.00, indicating a potential upside of 234.35%. Ernexa Therapeutics has a consensus target price of $30.00, indicating a potential upside of 646.27%. Given Ernexa Therapeutics' higher probable upside, analysts plainly believe Ernexa Therapeutics is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Evaxion A/S has higher revenue and earnings than Ernexa Therapeutics. Evaxion A/S is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.64	-$7.71M	-$1.21	N/A
Ernexa Therapeutics	$580K	11.30	-$14.08M	-$14.35	N/A

Evaxion A/S's return on equity of -61.43% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-61.43%	-34.23%
Ernexa Therapeutics	N/A	-305.93%	-169.86%

In the previous week, Evaxion A/S's average media sentiment score of 0.00 equaled Ernexa Therapeutics'average media sentiment score.

Company	Overall Sentiment
Evaxion A/S	Neutral
Ernexa Therapeutics	Neutral

Evaxion A/S has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.61, suggesting that its share price is 161% more volatile than the broader market.

Summary

Evaxion A/S beats Ernexa Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Ernexa Therapeutics compare to BeyondSpring?

Ernexa Therapeutics (NASDAQ:ERNA) and BeyondSpring (NASDAQ:BYSI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 0.5% of Ernexa Therapeutics shares are owned by company insiders. Comparatively, 29.3% of BeyondSpring shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Ernexa Therapeutics has a beta of 2.61, indicating that its stock price is 161% more volatile than the broader market. Comparatively, BeyondSpring has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market.

Ernexa Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 646.27%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Ernexa Therapeutics' average media sentiment score of 0.00 equaled BeyondSpring'saverage media sentiment score.

Company	Overall Sentiment
Ernexa Therapeutics	Neutral
BeyondSpring	Neutral

BeyondSpring has higher revenue and earnings than Ernexa Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	11.30	-$14.08M	-$14.35	N/A
BeyondSpring	$1.75M	14.77	-$1.01M	-$0.12	N/A

BeyondSpring's return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-305.93%	-169.86%
BeyondSpring	N/A	N/A	-28.88%

Summary

BeyondSpring beats Ernexa Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Ernexa Therapeutics compare to NextCure?

Ernexa Therapeutics (NASDAQ:ERNA) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Ernexa Therapeutics has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	11.30	-$14.08M	-$14.35	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

Ernexa Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 646.27%. NextCure has a consensus target price of $19.00, indicating a potential upside of 135.44%. Given Ernexa Therapeutics' higher probable upside, equities analysts plainly believe Ernexa Therapeutics is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

NextCure's return on equity of -154.62% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-305.93%	-169.86%
NextCure	N/A	-154.62%	-100.19%

Ernexa Therapeutics has a beta of 2.61, indicating that its share price is 161% more volatile than the broader market. Comparatively, NextCure has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

In the previous week, NextCure had 2 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 2 mentions for NextCure and 0 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.00 beat NextCure's score of -0.31 indicating that Ernexa Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Ernexa Therapeutics	Neutral
NextCure	Neutral

Summary

Ernexa Therapeutics and NextCure tied by winning 7 of the 14 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Atossa Genetics?

Atossa Genetics (NASDAQ:ATOS) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Ernexa Therapeutics has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A
Ernexa Therapeutics	$580K	11.30	-$14.08M	-$14.35	N/A

12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 9.8% of Atossa Genetics shares are owned by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Atossa Genetics' average media sentiment score of 0.00 equaled Ernexa Therapeutics'average media sentiment score.

Company	Overall Sentiment
Atossa Genetics	Neutral
Ernexa Therapeutics	Neutral

Atossa Genetics' return on equity of -102.99% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atossa Genetics	N/A	-102.99%	-85.78%
Ernexa Therapeutics	N/A	-305.93%	-169.86%

Atossa Genetics currently has a consensus target price of $20.33, suggesting a potential upside of 747.22%. Ernexa Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 646.27%. Given Atossa Genetics' stronger consensus rating and higher probable upside, equities analysts clearly believe Atossa Genetics is more favorable than Ernexa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Atossa Genetics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.61, suggesting that its stock price is 161% more volatile than the broader market.

Summary

Atossa Genetics beats Ernexa Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Ernexa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ERNA vs. The Competition

Export

Metric	Ernexa Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.84M	$3.91B	$7.23B	$12.88B
Dividend Yield	N/A	3.62%	2.55%	9.95%
P/E Ratio	-0.28	12.94	271.78	25.29
Price / Sales	11.30	1,459.61	709.75	112.40
Price / Cash	N/A	107.40	77.55	52.32
Price / Book	0.53	15.81	10.63	6.26
Net Income	-$14.08M	-$22.81M	$3.48B	$357.86M
7 Day Performance	-11.45%	-0.25%	-1.38%	-0.39%
1 Month Performance	-4.51%	4.91%	2.17%	-1.28%
1 Year Performance	-87.29%	44.99%	20.74%	11.50%

Ernexa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ERNA Ernexa Therapeutics	2.3323 of 5 stars	$4.02 -4.1%	$30.00 +646.3%	-86.5%	$6.84M	$580K	N/A	10
LTRN Lantern Pharma	0.2867 of 5 stars	$1.93 -4.5%	N/A	-54.7%	$25.82M	N/A	N/A	20	Positive News
EVAX Evaxion A/S	1.5969 of 5 stars	$3.07 +3.0%	$11.00 +258.3%	+7.5%	$24.85M	$7.53M	N/A	60
BYSI BeyondSpring	0.156 of 5 stars	$0.61 +1.4%	N/A	-67.4%	$24.78M	$1.75M	N/A	80
NXTC NextCure	3.3038 of 5 stars	$7.35 +8.1%	$19.00 +158.5%	+73.6%	$24.56M	N/A	N/A	90	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ERNA) was last updated on 9/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ernexa Therapeutics (ERNA) Competitors

ERNA vs. LTRN, EVAX, BYSI, NXTC, and ATOS

How does Ernexa Therapeutics compare to Lantern Pharma?

Summary

How does Ernexa Therapeutics compare to Evaxion A/S?

Summary

How does Ernexa Therapeutics compare to BeyondSpring?

Summary

How does Ernexa Therapeutics compare to NextCure?

Summary

How does Ernexa Therapeutics compare to Atossa Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERNA vs. The Competition

Ernexa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ernexa Therapeutics (ERNA) Competitors

ERNA vs. LTRN, EVAX, BYSI, NXTC, and ATOS

How does Ernexa Therapeutics compare to Lantern Pharma?

Do insiders and institutionals hold more shares of LTRN or ERNA?

Is LTRN or ERNA more profitable?

Does the media favor LTRN or ERNA?

Which has stronger earnings and valuation, LTRN or ERNA?

Do analysts prefer LTRN or ERNA?

Which has more risk and volatility, LTRN or ERNA?

Summary

How does Ernexa Therapeutics compare to Evaxion A/S?

Do analysts recommend EVAX or ERNA?

Do insiders and institutionals have more ownership in EVAX or ERNA?

Which has higher valuation & earnings, EVAX or ERNA?

Is EVAX or ERNA more profitable?

Does the media favor EVAX or ERNA?

Which has more risk & volatility, EVAX or ERNA?

Summary

How does Ernexa Therapeutics compare to BeyondSpring?

Do insiders and institutionals have more ownership in ERNA or BYSI?

Which has more volatility & risk, ERNA or BYSI?

Do analysts rate ERNA or BYSI?

Does the media refer more to ERNA or BYSI?

Which has higher earnings & valuation, ERNA or BYSI?

Is ERNA or BYSI more profitable?

Summary

How does Ernexa Therapeutics compare to NextCure?

Do institutionals & insiders believe in ERNA or NXTC?

Which has better valuation and earnings, ERNA or NXTC?

Do analysts rate ERNA or NXTC?

Is ERNA or NXTC more profitable?

Which has more risk and volatility, ERNA or NXTC?

Does the media favor ERNA or NXTC?

Summary

How does Ernexa Therapeutics compare to Atossa Genetics?

Which has stronger valuation and earnings, ATOS or ERNA?

Do institutionals & insiders hold more shares of ATOS or ERNA?

Does the media refer more to ATOS or ERNA?

Is ATOS or ERNA more profitable?

Do analysts recommend ATOS or ERNA?

Which has more risk and volatility, ATOS or ERNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERNA vs. The Competition

Ernexa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools